

Bio: Julia-Tatjana Maul

PD Dr. Julia-Tatjana Maul is a senior physician in the Department of Dermatology at the University Hospital of Zürich (USZ), Switzerland, and completed her habilitation at the Faculty of Medicine of the University of Zürich (UZH) awarding her the title of Privat Dozent (PD). She is the head of the clinical trials team in dermatology and leading physician of the psoriasis and hidradenitis suppurativa clinic. In addition, she is the principal investigator (PI) of several clinical trials such as the national PI of the Swiss psoriasis registry SDNTT (Swiss Dermatology Network for Targeted Therapy) and the International pustular psoriasis registry IRASPEN.

PD Dr. Maul graduated from Medical School at the University of Tübingen, Germany, in 2011. Between 2011 and 2013 she did part of her residency in the Oncology Department at the University Hospital of Zürich prior to transitioning to the department of Dermatology.

PD Dr. Maul's main research activities are aimed at inflammatory skin diseases. Since 2018, she has been leading her own research group at the USZ with the aim of elucidating gender differences and underlying immunological mechanisms, as well as differences in response and access to treatments, with a particular focus on psoriasis.

She holds a leadership position at the Global Psoriasis Atlas (GPA) as their `Global Medical Coordinator` and is a Councilor of the International Psoriasis Council (IPC). Furthermore, she is involved in the European Psoriasis Guidelines and co-authored the chapters' cancer, pregnancy, and diabetes.

Due to her strong interest in psoriasis-associated gender medicine she is a part of the commission "Sex and Gender in Medicine" of the Medical Faculty of the University of Zurich, American Women's Society of Dermatology and Co-Chair of the Pregnancy Task Force of the European Association of Dermatology and Venereology.

In recent years, she has been leading the international research project "Access to treatment" to facilitate access to medications and therapies for affected individuals around the globe with the `Global Healthcare Study on Psoriasis` (GHSP).